FP
REGN icon

Foundry Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Foundry Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,403
Closed -$22.6M – 347
2022
Q1 		$22.6M Sell
32,403
-715
-2% -$452K 1.15% 26
2021
Q4 		$20.9M Buy
+33,118
New +$20.4M 0.74% 40
2014
Q1 		– Sell
-15,860
Closed -$4.37M – 294
2013
Q4 		$4.37M Buy
+15,860
New +$4.56M 0.39% 93

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Foundry Partners's REGN Position: Q2 2022 in Review

Foundry Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 32,403 shares — an estimated $22.6M sold.

Foundry Partners first reported a position in REGN in Q4 2013 and held it in 3 quarters. The position peaked at $22.6M in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Foundry Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Foundry Partners sold 32,403 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $22.6M.
  • Foundry Partners first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Foundry Partners's Regeneron Pharmaceuticals position peaked at $22.6M in Q1 2022.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Foundry Partners's 13F filing for Q2 2022, filed 28 Jul 2022.